Europe Influenza Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 2,000.00$ 6,900.00

Europe Influenza Market: By Drug Class (Anti-viral drugs, Interferons, Vaccines), Route Of Administration (Oral, Parenteral, Others), By End User ( Hospital pharmacies Retail pharmacies Others) and Country

$ PRICE - $ 2,000.00$ 6,900.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Europe Influenza Market size was valued at USD 1.39 billion in 2021 and is expected to reach USD 2.6 billion by 2028, at a CAGR of 9.5% during the forecast period 2022-2028. The European market provides a detailed overview of the Europe Influenza market, and that can be segmented by drug class, by route of administration, and by end user. By drug class, The Europe Influenza market has been segmented into Anti-viral drugs, Interferons, Vaccines. The Platelet – Rich Plasma segment is likely to be the largest and fastest-growing segment in terms of drug class. The supremacy of this segment is owing to the end user of platelet-rich plasma therapy in bone degeneration disease. It was found that platelet-rich plasma therapy for curing knee osteoarthritis has a high success rate and the efficiency depends on the brutality of knee osteoarthritis. However, Cortisone or steroids is projected to grow with the fastest CAGR during the forecast period. It is mainly because corticosteroid injections can cure various spinal conditions and skeletal, and muscular. Dexamethasone, prednisone, methylprednisolone, and hydrocortisone are FDA-approved corticosteroid injections utilized to decrease inflammation and pain. Such characteristics of corticosteroid injections and their need for numerous bone diseases and injuries fuel the growth of the Bone Degeneration Therapeutics Market Share. The inactivated segment is estimated to hold the most dominant share of the global market. The demand for inactivated vaccines in developing and developed countries is due to the increasing focus of industrialists, as these are standardized according to the specific virus strain. This characteristic of the vaccines helps minimize the flu in less time and revert positive effects. The increasing demand, coupled with the high prevalence of influenza, is responsible for the highest CAGR of the segment during the forecast period. Based on the Route of administration, the Europe Influenza market is segmented into Oral, Parenteral Nutrition, and Others. Among these, the Parenteral segment is expected to have a significant growing market during the forecast period 2022-2028. Based on the End user, the Europe Influenza market is segmented Hospital pharmacies and Retail pharmacies, and Others. The Osteoarthritis segment accounts for the largest share in 2021. Hospital & retail pharmacies generated the highest revenue among the distribution channel segment in 2021. This leading position is attributable to the fact that vaccination is generally preferred and conducted at smaller institutions. In addition, the large vaccine supply from hospitals is expected to generate a high market value in the forthcoming years. Therefore, the hospital & retail pharmacies segment is also anticipated to witness the highest CAGR during the forecast period.

 

Key Developments:

In November 2020, European Commission approved Supemtek® which is a quadrivalent recombinant influenza vaccine for the protection against  influenza in adults of 18 years and older

Europe Influenza Market

MARKET SUMMARY
-
9.5%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 9.5%

Europe Influenza Market

  • The europe influenza market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The europe influenza market is segmented based on drug class, route of administration and end user and country
Key Players
  • AstraZeneca
  • Abbott Laboratories
  • BioCryst Pharmaceuticals
  • Emergent Biosolutions
  • GlaxoSmithKline

 

Europe Influenza Market Drivers

Europe Influenza market is chiefly driven by the growing prevalence of influenza, the government initiative on immunization programs, awareness about disease prevention, and progressions in the healthcare sector with growing vaccination rates.


Germany Got Significant Share

Europe Influenza Market

Germany, Italy, UK, France, Spain, Russia, and Poland market is expected to witness the highest market share during the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The Europe influenza market provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The Europe influenza market covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The Europe influenza market outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The Europe influenza market tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The Europe influenza market provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Europe Influenza Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The europe influenza market is projected to expand at a CAGR of 9.5% during the forecast period

AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline Plc. (U.K.), Novartis AG (Switzerland), Sanofi (France), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc. (U.S.), Abbott Laboratories Inc. (U.S.)


Report

Table Of Content

1.Executive summary

  1. Europe Influenza Market Introduction

2.1. Europe Influenza Market – Taxonomy

2.2. Europe Influenza Market –Definitions

2.2.1. Drug Class Type

2.2.2. Route of Administration

2.2.3. Distribution Channel

  1. Europe Influenza Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Europe Influenza Market Dynamics – Factors Impact Analysis

3.6. Europe Influenza Market – Regulations

3.7. Europe Influenza Market – Product Innovations

  1. Europe Influenza Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Oppurtunity Analysis

  1. Europe Influenza Market, By Drug Class, 2015 – 2019 and Forecast, 2020 – 2026

5.1. Anti-Viral Drugs

5.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3. Market Opportunity Analysis

5.1.3.1. Zanamivir

5.1.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

5.1.3.4. Oseltamivir

5.1.3.5. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.6. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.7. Market Opportunity Analysis

5.1.3.8. Amantadine

5.1.3.9. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.10. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.11. Market Opportunity Analysis

5.1.3.12. Rimantadine

5.1.3.13. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.14. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.15. Market Opportunity Analysis

5.1.3.16. Others

5.1.3.17. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.1.3.18. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.19. Market Opportunity Analysis

          5.2. Vaccines

5.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3. Market Opportunity Analysis

5.2.3.1. Trivalent

5.2.3.2. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.2.3.3. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3.4. Market Opportunity Analysis

5.2.3.5. Quadrivalent

5.2.3.6. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

5.2.3.7. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3.8. Market Opportunity Analysis

  1. Europe Influenza Market Forecast, By Route of Administration, 2015 – 2019 and Forecast, 2020 – 2026

6.1. Oral

6.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.3. Market Opportunity Analysis

6.2. Parenteral

6.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

6.3. Others

6.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.3.3. Market Opportunity Analysis

  1. Europe Influenza Market Forecast, By Distribution Channel, 2015 – 2019 and Forecast, 2020 – 2026

7.1. Hospital pharmacies

7.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Retail pharmacies

7.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Others

7.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

  1. Europe Influenza Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026

8.1. Drug Class Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

8.1.1. Anti-viral drugs

8.1.1.1. Zanamivir

8.1.1.2. Oseltamivir

8.1.1.3. Amantadine

8.1.1.4. Rimantadine

8.1.1.5. Others

8.1.1.6. Interferons

8.1.2. Vaccines

8.1.2.1. Trivalent

8.1.2.2. Quadrivalent

8.2. Route of Administration Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.2.1. Oral

8.2.2. Parenteral

8.2.3. Others

8.3. Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Others

8.4. Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.4.1. Germany

8.4.2. UK

8.4.3. France

8.4.4. Spain

8.4.5. Italy

8.4.6. Russia

8.4.7. Poland

8.4.8. Rest of Europe

8.5. Europe Influenza Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Country, 2018 – 2024

8.6. Europe Influenza Market Dynamics – Trends

  1. Competition Landscape

9.1. Strategic Dashboard of Top Market Players

9.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

9.2.1. AstraZeneca (UK)

9.2.2. F. Hoffmann-La Roche (Switzerland)

9.2.3. GlaxoSmithKline plc. (UK)

9.2.4. Novartis AG (Switzerland)

9.2.5. Sanofi (France)

9.2.6. Seqirus (UK)

9.2.7. Protein Sciences Corporation (U.S.)

9.2.8. Emergent Biosolutions (U.S.)

9.2.9. BioCryst Pharmaceuticals.Inc (U.S.)

9.2.10. Abbott Laboratories (U.S.)

  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • AstraZeneca (U.K.)
  • F. Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline Plc. (U.K.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Protein Sciences Corporation (U.S.)
  • Emergent Biosolutions (U.S.)
  • BioCryst Pharmaceuticals.Inc. (U.S.)
  • Abbott Laboratories Inc. (U.S.)

Description

Europe Influenza Market size was valued at USD 1.39 billion in 2021 and is expected to reach USD 2.6 billion by 2028, at a CAGR of 9.5% during the forecast period 2022-2028. The European market provides a detailed overview of the Europe Influenza market, and that can be segmented by drug class, by route of administration, and by end user. By drug class, The Europe Influenza market has been segmented into Anti-viral drugs, Interferons, Vaccines. The Platelet – Rich Plasma segment is likely to be the largest and fastest-growing segment in terms of drug class. The supremacy of this segment is owing to the end user of platelet-rich plasma therapy in bone degeneration disease. It was found that platelet-rich plasma therapy for curing knee osteoarthritis has a high success rate and the efficiency depends on the brutality of knee osteoarthritis. However, Cortisone or steroids is projected to grow with the fastest CAGR during the forecast period. It is mainly because corticosteroid injections can cure various spinal conditions and skeletal, and muscular. Dexamethasone, prednisone, methylprednisolone, and hydrocortisone are FDA-approved corticosteroid injections utilized to decrease inflammation and pain. Such characteristics of corticosteroid injections and their need for numerous bone diseases and injuries fuel the growth of the Bone Degeneration Therapeutics Market Share. The inactivated segment is estimated to hold the most dominant share of the global market. The demand for inactivated vaccines in developing and developed countries is due to the increasing focus of industrialists, as these are standardized according to the specific virus strain. This characteristic of the vaccines helps minimize the flu in less time and revert positive effects. The increasing demand, coupled with the high prevalence of influenza, is responsible for the highest CAGR of the segment during the forecast period. Based on the Route of administration, the Europe Influenza market is segmented into Oral, Parenteral Nutrition, and Others. Among these, the Parenteral segment is expected to have a significant growing market during the forecast period 2022-2028. Based on the End user, the Europe Influenza market is segmented Hospital pharmacies and Retail pharmacies, and Others. The Osteoarthritis segment accounts for the largest share in 2021. Hospital & retail pharmacies generated the highest revenue among the distribution channel segment in 2021. This leading position is attributable to the fact that vaccination is generally preferred and conducted at smaller institutions. In addition, the large vaccine supply from hospitals is expected to generate a high market value in the forthcoming years. Therefore, the hospital & retail pharmacies segment is also anticipated to witness the highest CAGR during the forecast period.

 

Key Developments:

In November 2020, European Commission approved Supemtek® which is a quadrivalent recombinant influenza vaccine for the protection against  influenza in adults of 18 years and older

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX